Emerging therapies for breast cancer

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xichun, Huang, Wei, Fan, Minhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410098/
https://www.ncbi.nlm.nih.gov/pubmed/28454587
http://dx.doi.org/10.1186/s13045-017-0466-3
_version_ 1783232607076483072
author Hu, Xichun
Huang, Wei
Fan, Minhao
author_facet Hu, Xichun
Huang, Wei
Fan, Minhao
author_sort Hu, Xichun
collection PubMed
description HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
format Online
Article
Text
id pubmed-5410098
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54100982017-05-02 Emerging therapies for breast cancer Hu, Xichun Huang, Wei Fan, Minhao J Hematol Oncol Review HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer. BioMed Central 2017-04-28 /pmc/articles/PMC5410098/ /pubmed/28454587 http://dx.doi.org/10.1186/s13045-017-0466-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Hu, Xichun
Huang, Wei
Fan, Minhao
Emerging therapies for breast cancer
title Emerging therapies for breast cancer
title_full Emerging therapies for breast cancer
title_fullStr Emerging therapies for breast cancer
title_full_unstemmed Emerging therapies for breast cancer
title_short Emerging therapies for breast cancer
title_sort emerging therapies for breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410098/
https://www.ncbi.nlm.nih.gov/pubmed/28454587
http://dx.doi.org/10.1186/s13045-017-0466-3
work_keys_str_mv AT huxichun emergingtherapiesforbreastcancer
AT huangwei emergingtherapiesforbreastcancer
AT fanminhao emergingtherapiesforbreastcancer

Ejemplares similares